Skip to main content

Advertisement

Log in

Screening for Cushing’s syndrome in obese type 2 diabetic patients and the predictive factors on the degree of serum cortisol suppression

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese type 2 diabetic patients devoid of specific clinical symptoms of Cushing’s syndrome. A total of 148 obese (BMI ≥30 kg/m2 ) type 2 diabetic patients (113 female, 35 male) were included in the study. An overnight 1-mg dexamethasone suppression test (DST) was performed on all patients. Suppression of serum cortisol to <1.8 μg/dL after administration of 1 mg dexamethasone was considered normal suppression. Low dose dexamethasone suppression test was performed on the patients who had serum cortisol level over 1.8 μg/dL after overnight 1 mg DST. Regression analysis was applied to determine the effective factors on suppression of serum cortisol. Mean age, BMI and HbA1c levels respectively were 50,82 ± 8,50 year, 31,78 ± 4,66 kg/m2, %8,96 ± 2,42 in males and 54,15 ± 10,348 year, 34,32 ± 5.71 kg/m2, % 8,18 ± 2,06 in females. Serum cortisol level was found 1.64 ± 5.62 μg/dl after overnight DST. A total of 9 (6.2 %) patients had non-suppressible overnight DST. Only four (2.6 %) of these patients were diagnosed with Cushing Syndrome after low-dose DST. Diagnosis was confirmed pathologically. Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (2 patients) and adrenocortical adenoma (2 patients). Age and duration of diabetes was found to be related to the degree of suppression. Cushing’s syndrome should be investigated in high-risk groups like uncontrolled diabetes, obesity. All the related factors on the degree of suppression must be considered for the final diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslin’s Diabetes Mellitus. 14th ed. Boston: Lippincott Williams-Wilkins; 2005.

    Google Scholar 

  2. Khan R. Weight gain and insulin therapy. Br J Diabetes Vasc Dis. 2004;4:264–7.

    Article  Google Scholar 

  3. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalance of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205–11.

    Article  PubMed  CAS  Google Scholar 

  4. De Groot LJ, editor. Endocrinology. 5th ed. Philadelphia: WB Saunders; 2001.

    Google Scholar 

  5. Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clin Endocrinol Metab. 2001;86:5301–6.

    Article  PubMed  CAS  Google Scholar 

  6. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.

    Article  PubMed  CAS  Google Scholar 

  7. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergot N, et al. Occult Cushing’s syndrome in type-2 ciabetes. J Clin Endocrinol Metab. 2003;12:5808–13.

    Article  Google Scholar 

  8. Tabarin A, Perez P. Pros and cons of screening for occult Cushing syndrome. Nat Rev Endocrinol. 2011;7:445–55.

    Article  PubMed  Google Scholar 

  9. Caetano MS, Silva Rdo C, Kater CE. Increased diagnostic probability of subclinical Cushing’s syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2007;51:1118–27.

    Article  PubMed  Google Scholar 

  10. Reimondo G, Pia A, Allasino B, Tassone F, Bovio S, Borretta G, et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol. 2007;67:225–9.

    Article  CAS  Google Scholar 

  11. Christy NP. Harvey Cushing as clinical investigator and laboratory worker. Am J Med Sci. 1981;281:79–96.

    Article  PubMed  CAS  Google Scholar 

  12. Yanovski JA, Cutler Jr GB. Glucocorticoid action and the clinical features of Cushing’s syndrome. Endocrinol Metab Clin North Am. 1994;23:487–509.

    PubMed  CAS  Google Scholar 

  13. Leibowitz G, Tsur A, Chayen SD, et al. Preclinical Cushing’s syndrome: an unexpected frequent cause of poor glycemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44:717–22.

    Article  CAS  Google Scholar 

  14. Tiryakioglu O,Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO et al. Screening for Cushing's syndrome in obese patients. Clinics 2010. http://dx.doi.org/10.1590/S1807-59322010000100003.

  15. Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.

    Article  PubMed  CAS  Google Scholar 

  16. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, et al. Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res. 2002;10:1217–21.

    Article  PubMed  CAS  Google Scholar 

  17. Sahin M, Kebapcilar L, Taslipinar A, Azal O, Ozgurtas T, Corakci A, et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med. 2009;48:33–9.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mustafa Temizel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mert, M., Temizel, M., Erol, S. et al. Screening for Cushing’s syndrome in obese type 2 diabetic patients and the predictive factors on the degree of serum cortisol suppression. Int J Diabetes Dev Ctries 32, 199–202 (2012). https://doi.org/10.1007/s13410-012-0091-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-012-0091-1

Keywords

Navigation